1st International consensus guidelines for advanced breast cancer (ABC 1)

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018

“…If the leading site of metastasis has been proven to be hormone receptor negative (preferen tially diagnosed by biopsy of at least 1 metastatic lesion) or if the course of the disease suggests endocrine resistance or ur gent need of response, cytotoxic chemotherapy is indicated (LoE 1aA, AGO++). This is in accordance with the recently published First International Consensus Guidelines for Ad vanced Breast Cancer (ABC 1) [12]. The use of anthracyclines (including liposomal anthra cyclines) and taxanes remains state of the art in first line therapy of metastatic breast cancer.…”

Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer

“…Chemotherapy is the recommended treatment when there is clear evidence of resistance to HT. The international consensus guidelines for advanced BC concur with the European guidelines regarding the use of HT as first choice and as a subsequent option following disease progression; however, no guidance is provided on the use of more than two lines of HT or criteria for switching to chemotherapy 2 . The National Comprehensive Cancer Network guidelines recommend continuing HT regimens as long as clinical benefit was received from the previous HT regimen, without a clear definition of clinical benefit.…”

“…Guidelines for the number of lines of hormonal therapy (HT) that should be used and when to initiate chemotherapy in patients with hormonereceptor-positive (HR þ ) advanced breast cancer (BC) are not straightforward [1][2][3] . This is due in part to the currently incomplete evidence base for the recommendations, which can make the optimal treatment strategy open to interpretation.…”

“…Understanding the reasons for differences between 'real-world' treatment decisions and guideline recommendations will enable further guideline clarification. Furthermore, lack of adherence to the guideline-recommended treatments may negatively affect quality of care in patients with BC 2,[7][8][9] . This chart review is the first that evaluates actual physician-reported treatments from adjuvant therapy to completion of three lines of treatment in the advanced BC setting for the purpose of providing evidence of HT and chemotherapy treatment patterns in Europe and assessing the results against guideline recommendations in order to highlight issues requiring further clarification.…”

Significance of Echocardiography in the Assessment of Left Ventricular Function in Patients Receiving Combined Adjuvant Treatment with Anthracyclines and Trastuzumab / Značaj ehokardiografije u proceni funkcije leve komore kod bolesnica na adjuvantnoj terapji (kombinovana terapija antraciklinima i trastuzumabom)

“…In an adjuvant approach to the treatment, this receptor considerably reduces the risk of relapse and death, while in the neoadjuvant approach it contributes to a far more significant, complete pathological response of the HER2-positive breast cancer types. The application of trastuzumab carries a small to moderate risk of cardiotoxicity that is manifested by an asymptomatic decrease in the left ventricular ejection fraction, and rarely leads to clinical manifestations of heart failure (3)(4)(5). Because of the risk of cardiac dysfunction that is associated with the trastuzumab therapy, the cardiac function must be carefully monitored.…”